A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome - PubMed
4 hours ago
- #Metabolic Syndrome
- #Nanomedicine
- #SGLT2 Inhibition
- A kidney-targeted nanocarrier (T-PAAD NPs) is developed for site-specific inhibition of SGLT2 to treat cardiovascular-kidney-metabolic (CKM) syndrome.
- The nanocarrier releases empagliflozin (EMPA) selectively in renal tubules in response to high urea levels, improving renal specificity and reducing systemic side effects.
- It combines reactive oxygen species (ROS) scavenging with drug delivery to mitigate oxidative stress and enhance therapeutic outcomes.
- In mouse models of CKM, T-PAAD NPs/EMPA outperformed free EMPA, improving glycemic control, renal function, and cardiovascular health.
- This bioresponsive platform offers a promising strategy for treating systemic metabolic disorders by integrating targeted drug release with metabolic modulation.